Enzon Pharmaceuticals (ENZN) 10-K2024 FY Annual report

Filed: 21 Feb 25, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: affiliate, allocate, allocating, appointment, ASU, Codification, CODM, comparison, contacted, delegated, explore, exploring, formulate, interim, Jaffray, maker, member, organization, reached, segment, slightly, Stephen, Topic, Viskase

Removed: charged, Chile, claimed, Cover, Document, driven, excluded, Extension, formatted, granted, guidance, informed, Inline, Instance, Interactive, irrespective, Japan, July, language, liable, Linkbase, Malaysia, minimal, order, overpaid, recoupment, remain, resulted, Schema, Taxonomy, therapeutic, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENZN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement of Enzon Pharmaceuticals, Inc. and Subsidiaries on Form S-1 (No. 333-250031) of our report dated February 21, 2025, on our audits of the financial statements as of December 31, 2024 and 2023 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about February 21, 2025.

/s/ EisnerAmper LLP

EISNERAMPER LLP

Philadelphia, Pennsylvania

February 21, 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.